Document is current

Article History

Received: 9 December 2023

Accepted: 10 April 2024

First Online: 22 May 2024

Competing interests

: K.K. is an employee and shareholder of Cynata Therapeutics, which funded the work described in this manuscript. D.T.Y. reports honoraria and research funding from Novartis. J.E.J.R. holds shares in Rarecyte and Woke Pharmaceuticals; reports data safety and monitoring board membership for the Fanconi anemia trial; has received grant and research support from the National Health and Medical Research Council (Investigator Grant), Cancer Council New South Wales, the Cancer Institute of New South Wales, the Medical Research Future Fund, Therapeutic Innovation Australia and philanthropic foundations; reports supply of material (via a material transfer agreement) or consultancy or honoraria from Rarecyte, Novartis, bluebird bio, Spark Therapeutics, Cynata Therapeutics, Pfizer and CRISPR Therapeutics; he reports membership on an entity’s board of directors or advisory committees as co-founder of AAVec Bio and nonexecutive director of Kennerton Capital; and is employed by the Sydney Local Health District at Royal Prince Alfred Hospital as Head of the Department of Cell & Molecular Therapies. A.J.C.B., J.E.G. and R.R. declare no competing interests.